Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.11, $0.09 better than the analyst estimate of $0.02. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Earnings

Catalyst Pharmaceutical Partners (CPRX) PT Raised to $11 at SunTrust August 8, 2019 1:03 PM Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate UpdateAugust 7, 2019 4:19 PM